Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
- IRB Number: 1811447298 (IUSCC-0664)
- Research Study Identifier: TX10501
- Principal Investigator: Patrick Loehrer, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required